A Phase 3 interventional study of Eravacycline and Ertapenem in Complicated Intra-abdominal Infections, sponsored by Tetraphase Pharmaceuticals, Inc.. Completed at 69 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-01-11.
Sponsored by Tetraphase Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Intraabdominal Infections with a site in United States — 3 open to participants now, 5 under way, none of them phase 3. Intraabdominal Infections · United States.
Among the 29 studies in Intraabdominal Infections with a site in United States, this one is the 2nd largest by enrollment of the 24 interventional ones that give a count, is one of 3 that started in 2013, is one of 9 in phase 3, and was the 12th registered.
129 studies on the registry are indexed under Intraabdominal Infections; 15 are open to participants now.
Browse Intraabdominal Infections studies →3 of the 29 studies in Intraabdominal Infections with a site in United States are open now. Recruiting first, the newest first:
True Bearing Diagnostics, Inc. · Sites in United States
Ages 7+ · Healthy volunteers
Tetraphase Pharmaceuticals, Inc · Sites in United States
Ages 8–17
Washington University School of Medicine · Sites in United States
Ages 18–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 10 Intraabdominal Infections studies recruiting now, 6 (60%) set no upper age limit and 3 (30%) stop at 75 or younger; 2 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 11 · Phase 3 10 · Phase 4 1
First in 2007; this study’s year is marked. 3 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 541 is above the median of 140 across 77 interventional studies indexed under Intraabdominal Infections.
Median enrollment 144 across the 24 interventional studies, 1,000 across the 5 observational. Of the 23 that completed or were terminated, 19 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 29 have an industry lead sponsor. The 10 most frequent:
Tetraphase Pharmaceuticals, Inc. is the lead sponsor of 15 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 2 (33%) have results posted.
Tetraphase Pharmaceuticals, Inc. has 3 studies filed under Intraabdominal Infections — fewer than ten, so there is no comparison to draw.
1 of the studies in Intraabdominal Infections with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07579312True Bearing Diagnostics, Inc.Diagnosis of Abdominal Pain Using RNA Levels: The NATURAL Study | 2027-04 |
Add it to your calendar (.ics) → With an account.
Among the 29 studies in Intraabdominal Infections with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase 3, randomized, double-blind, double-dummy, multicenter, prospective study to assess the efficacy, safety, and pharmacokinetics of eravacycline compared with ertapenem in the treatment of adult complicated intra-abdominal infections (cIAI).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Antibiotic-related exclusions:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Eravacycline was administered intravenously (IV) at a dose of 1.0 milligram per kilogram of body weight (mg/kg) every 12 hours (q12h) for a minimum of 4 days and a maximum of 14 days. Eravacycline treatment was to be stopped when symptoms of complicated intra-abdominal infection (cIAI) resolved, there was treatment failure, or the maximum allowed number of infusion days was reached.
Drug: Eravacycline · Drug: Placebo
Ertapenem was administered IV at a dose of 1.0 gram (g) every 24 hours (q24h) for a minimum of 4 days and a maximum of 14 days. Ertapenem treatment was to be stopped when symptoms of cIAI resolved, there was treatment failure, or the maximum allowed number of infusion days was reached.
Drug: Ertapenem · Drug: Placebo
Also known as: TP-434
Also known as: Invanz
Administered IV to maintain the blind.
Clinical Response of Eravacycline and Ertapenem Treatment Arms at the Test-of-cure (TOC) Visit in the Microbiological Intent-to-treat (Micro-ITT) Population
Clinical response was classified as cure (complete resolution or significant improvement of signs and symptoms of the index infection), failure (death related to complicated intra-abdominal infection \[cIAI\], unplanned surgical procedures or percutaneous drainage procedures, persisting or recurrent infection within the abdomen, postsurgical wound infection, or administration of effective concomitant antibacterial therapy), or indeterminate (outcome was neither cure nor failure, or assessment was not available). Participants who were failures at the End-of-Treatment (EOT) visit (within 24 hours of last dose) were considered failures at the TOC visit. The number of participants with a clinical response classification of cure, failure, or indeterminate is presented.
Time frame: TOC visit: 25-31 days after the first dose of study drug
Clinical Response of Eravacycline and Ertapenem Treatment Arms in the Modified Intent-to-treat (MITT) Population at the TOC Visit
Clinical response was classified as cure (complete resolution or significant improvement of signs and symptoms of the index infection), failure (death related to complicated intra-abdominal infection \[cIAI\], unplanned surgical procedures or percutaneous drainage procedures, persisting or recurrent infection within the abdomen, postsurgical wound infection, or administration of effective concomitant antibacterial therapy), or indeterminate (outcome was neither cure nor failure, or assessment was not available). Participants who were failures at the EOT visit (within 24 hours of last dose) were considered failures at the TOC visit. The number of participants with a clinical response classification of cure, failure, or indeterminate is presented.
Time frame: TOC visit: 25-31 days after first dose
Clinical Response of Eravacycline and Ertapenem Treatment Arms in the Clinically Evaluable (CE) Population at the TOC Visit
Clinical response was classified as cure (complete resolution or significant improvement of signs and symptoms of the index infection), failure (death related to complicated intra-abdominal infection \[cIAI\], unplanned surgical procedures or percutaneous drainage procedures, persisting or recurrent infection within the abdomen, postsurgical wound infection, or administration of effective concomitant antibacterial therapy), or indeterminate (outcome was neither cure nor failure, or assessment was not available). Participants who were failures at the EOT visit (within 24 hours of last dose) were considered failures at the TOC visit. The number of participants with a clinical response classification of cure, failure, or indeterminate is presented.
Time frame: TOC visit: 25-31 days after first dose
| Milestone | Eravacycline, 1.0 mg/kg q12h | Ertapenem, 1.0 g q24h |
|---|---|---|
| Started | 270 | 271 |
| Received at least 1 dose of study drug | 270 | 268 |
| Completed | 246 | 255 |
| Not completed | 24 | 16 |
| Withdrew: Lost to follow-up | 15 | 3 |
| Withdrew: Adverse event | 3 | 6 |
| Withdrew: Withdrawal by subject | 3 | 2 |
| Withdrew: Noncompliance | 2 | 3 |
| Withdrew: Enterococcus resistant | 0 | 1 |
| Withdrew: Inadvertently not scheduled | 1 | 0 |
| Withdrew: Randomized but was a screen failure | 0 | 1 |
Clinical response was classified as cure (complete resolution or significant improvement of signs and symptoms of the index infection), failure (death related to complicated intra-abdominal infection \[cIAI\], unplanned surgical procedures or percutaneous drainage procedures, persisting or recurrent infection within the abdomen, postsurgical wound infection, or administration of effective concomitant antibacterial therapy), or indeterminate (outcome was neither cure nor failure, or assessment was not available). Participants who were failures at the End-of-Treatment (EOT) visit (within 24 hours of last dose) were considered failures at the TOC visit. The number of participants with a clinical response classification of cure, failure, or indeterminate is presented.
| participants | Eravacycline, 1.0 mg/kg q12h | Ertapenem, 1.0 g q24h |
|---|---|---|
| Cure | 191 | 198 |
| Failure | 19 | 11 |
| Indeterminate | 10 | 17 |
Clinical response was classified as cure (complete resolution or significant improvement of signs and symptoms of the index infection), failure (death related to complicated intra-abdominal infection \[cIAI\], unplanned surgical procedures or percutaneous drainage procedures, persisting or recurrent infection within the abdomen, postsurgical wound infection, or administration of effective concomitant antibacterial therapy), or indeterminate (outcome was neither cure nor failure, or assessment was not available). Participants who were failures at the EOT visit (within 24 hours of last dose) were considered failures at the TOC visit. The number of participants with a clinical response classification of cure, failure, or indeterminate is presented.
| participants | Eravacycline, 1.0 mg/kg q12h | Ertapenem, 1.0 g q24h |
|---|---|---|
| Cure | 235 | 238 |
| Failure | 19 | 15 |
| Indeterminate | 16 | 15 |
Clinical response was classified as cure (complete resolution or significant improvement of signs and symptoms of the index infection), failure (death related to complicated intra-abdominal infection \[cIAI\], unplanned surgical procedures or percutaneous drainage procedures, persisting or recurrent infection within the abdomen, postsurgical wound infection, or administration of effective concomitant antibacterial therapy), or indeterminate (outcome was neither cure nor failure, or assessment was not available). Participants who were failures at the EOT visit (within 24 hours of last dose) were considered failures at the TOC visit. The number of participants with a clinical response classification of cure, failure, or indeterminate is presented.
| participants | Eravacycline, 1.0 mg/kg q12h | Ertapenem, 1.0 g q24h |
|---|---|---|
| Cure | 222 | 225 |
| Failure | 17 | 13 |
| Indeterminate | 0 | 0 |
Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Eravacycline, 1.0 mg/kg q12h | — | 17/270 (6.3%) | 43/270 (15.9%) |
| Ertapenem, 1.0 g q24h | — | 16/268 (6%) | 28/268 (10.4%) |
| Event | Eravacycline, 1.0 mg/kg q12h | Ertapenem, 1.0 g q24h |
|---|---|---|
| Abdominal abscessInfections and infestations | 1/270 | 2/268 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/270 | 2/268 |
| PneumoniaInfections and infestations | 2/270 | 1/268 |
| Wound dehiscenceInjury, poisoning and procedural complications | 2/270 | 1/268 |
| Atrial fibrillationCardiac disorders | 0/270 | 1/268 |
| Cardiopulmonary failureCardiac disorders | 0/270 | 1/268 |
| Pulseless electrical activityCardiac disorders | 0/270 | 1/268 |
| Supraventricular tachycardiaCardiac disorders | 0/270 | 1/268 |
| Abdominal compartment syndromeGastrointestinal disorders | 0/270 | 1/268 |
| Colonic fistulaGastrointestinal disorders | 0/270 | 1/268 |
| Event | Eravacycline, 1.0 mg/kg q12h | Ertapenem, 1.0 g q24h |
|---|---|---|
| NauseaGastrointestinal disorders | 22/270 | 2/268 |
| VomitingGastrointestinal disorders | 11/270 | 9/268 |
| AnaemiaBlood and lymphatic system disorders | 7/270 | 9/268 |
| PyrexiaGeneral disorders | 6/270 | 8/268 |
| PhlebitisVascular disorders | 8/270 | 1/268 |
All randomized participants (Intent-to-treat \[ITT\] population)
| Age, Continuous(years) | Eravacycline, 1.0 mg/kg q12h | Ertapenem, 1.0 g q24h | Total |
|---|---|---|---|
| Mean | 54.8 ± 16.92 | 54.8 ± 16.09 | 54.8 ± 16.49 |
| Sex: Female, Male(Participants) | Eravacycline, 1.0 mg/kg q12h | Ertapenem, 1.0 g q24h | Total |
|---|---|---|---|
| Female | 114 | 108 | 222 |
| Male | 156 | 163 | 319 |
| Ethnicity (NIH/OMB)(Participants) | Eravacycline, 1.0 mg/kg q12h | Ertapenem, 1.0 g q24h | Total |
|---|---|---|---|
| Hispanic or Latino | 8 | 9 | 17 |
| Not Hispanic or Latino | 261 | 262 | 523 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Race/Ethnicity, Customized(participants) | Eravacycline, 1.0 mg/kg q12h | Ertapenem, 1.0 g q24h | Total |
|---|---|---|---|
| White | 263 | 260 | 523 |
| Black or African American | 1 | 3 | 4 |
| Asian | 1 | 3 | 4 |
| Other Race | 4 | 5 | 9 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Region of Enrollment(participants) | Eravacycline, 1.0 mg/kg q12h | Ertapenem, 1.0 g q24h | Total |
|---|---|---|---|
| Russian Federation | 28 | 24 | 52 |
| Romania | 42 | 42 | 84 |
| United States | 18 | 20 | 38 |
| Ukraine | 38 | 38 | 76 |
| Czech Republic | 14 | 17 | 31 |
| Latvia | 25 | 23 | 48 |
| South Africa | 0 | 1 | 1 |
| Bulgaria | 45 | 44 | 89 |
| Lithuania | 26 | 26 | 52 |
| Germany | 2 | 2 | 4 |
| Estonia | 32 | 34 | 66 |
The record gives a start of Aug 2013, a primary completion of Aug 2014 and a completion of Aug 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2016, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Eravacycline
Tetraphase Pharmaceuticals, Inc.